Richard Morphy

3.4k total citations · 2 hit papers
16 papers, 2.6k citations indexed

About

Richard Morphy is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Richard Morphy has authored 16 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Organic Chemistry and 8 papers in Computational Theory and Mathematics. Recurrent topics in Richard Morphy's work include Computational Drug Discovery Methods (8 papers), Click Chemistry and Applications (7 papers) and Chemical Synthesis and Analysis (6 papers). Richard Morphy is often cited by papers focused on Computational Drug Discovery Methods (8 papers), Click Chemistry and Applications (7 papers) and Chemical Synthesis and Analysis (6 papers). Richard Morphy collaborates with scholars based in United Kingdom, France and Japan. Richard Morphy's co-authors include Zoran Ranković, Corinne Kay, David C. Rees, David Gani, Andrew Mountain, John Porter, N. Willmott, Andrew Docherty, Surinder K. Chander and Andrew T. Millican and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmaceutical Sciences and Tetrahedron Letters.

In The Last Decade

Richard Morphy

16 papers receiving 2.5k citations

Hit Papers

Designed Multiple Ligands. An Emerging Drug Discovery Par... 2004 2026 2011 2018 2005 2004 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
    2005 1.0k citations Richard Morphy, Zoran Ranković Journal of Medicinal Chemistry profile →
  2. From magic bullets to designed multiple ligands
    2004 583 citations Richard Morphy, Corinne Kay et al. Drug Discovery Today profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Morphy United Kingdom 12 1.3k 932 804 623 286 16 2.6k
Patrick Dallemagne France 28 996 0.8× 1.5k 1.6× 596 0.7× 665 1.1× 214 0.7× 147 3.0k
Michael S. Malamas United States 27 1.5k 1.1× 1.2k 1.3× 461 0.6× 610 1.0× 161 0.6× 71 3.3k
Joaquín M. Campos Rosa Spain 33 1.6k 1.2× 1.3k 1.4× 495 0.6× 384 0.6× 167 0.6× 164 3.5k
Caterina Fattorusso Italy 33 1.3k 1.0× 1.0k 1.1× 442 0.5× 566 0.9× 274 1.0× 94 2.8k
Zoran Ranković United States 23 2.3k 1.7× 1.4k 1.5× 923 1.1× 763 1.2× 666 2.3× 67 4.0k
Adriano Martinelli Italy 36 1.9k 1.5× 1.2k 1.2× 505 0.6× 667 1.1× 308 1.1× 163 3.7k
Li Di United States 13 767 0.6× 490 0.5× 533 0.7× 613 1.0× 152 0.5× 18 2.0k
William J. Greenlee United States 34 2.2k 1.7× 2.0k 2.1× 429 0.5× 338 0.5× 642 2.2× 161 4.5k
Shi‐Liang Huang China 37 1.3k 1.0× 942 1.0× 415 0.5× 593 1.0× 97 0.3× 116 3.2k
Philippe Chavatte France 26 1.2k 0.9× 707 0.8× 207 0.3× 504 0.8× 280 1.0× 85 2.5k

Countries citing papers authored by Richard Morphy

Since Specialization
Citations

This map shows the geographic impact of Richard Morphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Morphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Morphy more than expected).

Fields of papers citing papers by Richard Morphy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Morphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Morphy. The network helps show where Richard Morphy may publish in the future.

Co-authorship network of co-authors of Richard Morphy

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Morphy. A scholar is included among the top collaborators of Richard Morphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Morphy. Richard Morphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ray, Peter C., Jane Wright, Julia Adam, et al.. (2010). Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(4). 1084–1088. 18 indexed citations
2.
Bingham, Matilda, Richard Goodwin, Anders Haunsø, et al.. (2010). The identification, and optimisation of hERG selectivity, of a mixed NET/SERT re-uptake inhibitor for the treatment of pain. Bioorganic & Medicinal Chemistry Letters. 21(1). 271–275. 3 indexed citations
3.
Moir, Elizabeth M., Phillip M. Cowley, Morag Ferguson, et al.. (2010). Design, synthesis, and structure–activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists. Bioorganic & Medicinal Chemistry Letters. 20(24). 7327–7330. 16 indexed citations
4.
Ranković, Zoran & Richard Morphy. (2010). Lead Generation Approaches in Drug Discovery. 11 indexed citations
5.
Morphy, Richard & Zoran Ranković. (2009). Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges. Current Pharmaceutical Design. 15(6). 587–600. 219 indexed citations
6.
Morphy, Richard. (2009). Selectively Nonselective Kinase Inhibition: Striking the Right Balance. Journal of Medicinal Chemistry. 53(4). 1413–1437. 203 indexed citations
7.
Morphy, Richard & Zoran Ranković. (2006). Fragments, network biology and designing multiple ligands. Drug Discovery Today. 12(3-4). 156–160. 159 indexed citations
8.
Morphy, Richard & Zoran Ranković. (2006). The Physicochemical Challenges of Designing Multiple Ligands. Journal of Medicinal Chemistry. 49(16). 4961–4970. 143 indexed citations
9.
Morphy, Richard & Zoran Ranković. (2006). Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. ChemInform. 37(6). 10 indexed citations
10.
Morphy, Richard. (2006). The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds. Journal of Medicinal Chemistry. 49(10). 2969–2978. 82 indexed citations
11.
Morphy, Richard & Zoran Ranković. (2005). Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. Journal of Medicinal Chemistry. 48(21). 6523–6543. 1002 indexed citations breakdown →
12.
Palin, Ronald, John K. Clark, Jean E. Cottney, et al.. (2004). Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists. Bioorganic & Medicinal Chemistry Letters. 15(3). 589–593. 10 indexed citations
13.
Morphy, Richard, Corinne Kay, & Zoran Ranković. (2004). From magic bullets to designed multiple ligands. Drug Discovery Today. 9(15). 641–651. 583 indexed citations breakdown →
14.
Wang, Xiaoen, N. Willmott, Surinder K. Chander, et al.. (1997). Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clinical & Experimental Metastasis. 15(2). 184–195. 48 indexed citations
15.
Morphy, Richard, et al.. (1997). Resin-immobilised benzyl and aryl vinyl sulfones: New versatile traceless linkers for solid-phase organic synthesis. Tetrahedron Letters. 38(49). 8573–8576. 53 indexed citations
16.
Chander, Surinder K., Pari Antoniw, Nigel R. A. Beeley, et al.. (1995). An in Vivo Model for Screening Peptidomimetic Inhibitors of Gelatinase A. Journal of Pharmaceutical Sciences. 84(4). 404–409. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Dallemagne Breakdown of academic impact, for papers by Michael S. Malamas Breakdown of academic impact, for papers by Joaquín M. Campos Rosa Breakdown of academic impact, for papers by Caterina Fattorusso Breakdown of academic impact, for papers by Zoran Ranković Breakdown of academic impact, for papers by Adriano Martinelli Breakdown of academic impact, for papers by Li Di Breakdown of academic impact, for papers by William J. Greenlee Breakdown of academic impact, for papers by Shi‐Liang Huang Breakdown of academic impact, for papers by Philippe Chavatte
Rankless by CCL
2026